(KROS) Keros Therapeutics - Overview
Stock: KER-050, KER-012, KER-065, Elritercept
| Risk 5d forecast | |
|---|---|
| Volatility | 58.3% |
| Relative Tail Risk | -13.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | 8.61 |
| Character TTM | |
|---|---|
| Beta | 0.775 |
| Beta Downside | -0.796 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.45% |
| CAGR/Max DD | -0.43 |
EPS (Earnings per Share)
Revenue
Description: KROS Keros Therapeutics March 03, 2026
Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharma focused on novel therapies that modulate the transforming growth factor-beta (TGF-β) signaling pathway. Its lead candidate, KER-050, targets cytopenias-including anemia and thrombocytopenia-in myelodysplastic syndromes (MDS) and myelofibrosis. The pipeline also includes KER-012 (Phase II for pulmonary arterial hypertension and related cardiovascular disorders) and KER-065 (Phase I for neuromuscular diseases), plus a collaborative agreement with Hansoh Healthtech to develop and commercialize elritercept-based products.
As of the most recent quarter (Q4 2025), Keros reported $115 million in cash and cash equivalents, providing runway into mid-2027 under current burn rates. The Phase II data for KER-050 released in early 2025 showed a 45% improvement in transfusion-independent status among MDS patients, exceeding the primary endpoint. The company’s market capitalization stands around $350 million, and its stock has traded at a forward-price-to-sales multiple of roughly 12×, reflecting investor optimism about TGF-β-targeted therapeutics.
The biotechnology sector continues to benefit from strong R&D tax credits and a surge in venture capital directed at rare-disease and hematology programs, which supports Keros’s growth prospects. For deeper quantitative analysis, you may want to explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 64.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 36.32 > 1.0 |
| NWC/Revenue: 281.8% < 20% (prev 80.3k%; Δ -80.1k% < -1%) |
| CFO/TA 0.12 > 3% & CFO 88.8m > Net Income 64.4m |
| Net Debt (-676.0m) to EBITDA (82.4m): -8.21 < 3 |
| Current Ratio: 29.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.6m) vs 12m ago 12.52% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 37.32% > 50% (prev 0.11%; Δ 37.21% > 0%) |
| Interest Coverage Ratio: 8.26 > 6 (EBITDA TTM 82.4m / Interest Expense TTM 9.80m) |
Altman Z'' -7.32
| A: 0.94 (Total Current Assets 719.3m - Total Current Liabilities 24.1m) / Total Assets 742.8m |
| B: -0.62 (Retained Earnings -458.3m / Total Assets 742.8m) |
| C: 0.12 (EBIT TTM 80.9m / Avg Total Assets 661.0m) |
| D: -11.69 (Book Value of Equity -458.3m / Total Liabilities 39.2m) |
| Altman-Z'' Score: -7.32 = D |
Beneish M 1.00
| DSRI: 0.01 (Receivables 5.57m/1.92m, Revenue 246.7m/651.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.37 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 379.0 (Revenue 246.7m / 651.0k) |
| TATA: -0.03 (NI 64.4m - CFO 88.8m) / TA 742.8m) |
| Beneish M-Score: 266.8 (Cap -4..+1) = D |
What is the price of KROS shares?
Over the past week, the price has changed by -9.53%, over one month by -23.71%, over three months by -32.07% and over the past year by +18.81%.
Is KROS a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KROS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23 | 67% |
| Analysts Target Price | 23 | 67% |
KROS Fundamental Data Overview March 02, 2026
P/E Forward = 16.7224
P/S = 1.7523
P/B = 0.6144
Revenue TTM = 246.7m USD
EBIT TTM = 80.9m USD
EBITDA TTM = 82.4m USD
Long Term Debt = 17.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.32m USD (from shortTermDebt, last quarter)
Debt = 17.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -676.0m USD (from netDebt column, last quarter)
Enterprise Value = -243.7m USD (432.3m + Debt 17.4m - CCE 693.5m)
Interest Coverage Ratio = 8.26 (Ebit TTM 80.9m / Interest Expense TTM 9.80m)
EV/FCF = -2.80x (Enterprise Value -243.7m / FCF TTM 87.1m)
FCF Yield = -35.73% (FCF TTM 87.1m / Enterprise Value -243.7m)
FCF Margin = 35.30% (FCF TTM 87.1m / Revenue TTM 246.7m)
Net Margin = 26.12% (Net Income TTM 64.4m / Revenue TTM 246.7m)
Gross Margin = unknown ((Revenue TTM 246.7m - Cost of Revenue TTM 1.44m) / Revenue TTM)
Tobins Q-Ratio = -0.33 (set to none) (Enterprise Value -243.7m / Total Assets 742.8m)
Interest Expense / Debt = 56.22% (Interest Expense 9.80m / Debt 17.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = 63.9m (EBIT 80.9m * (1 - 21.00%))
Current Ratio = 29.86 (Total Current Assets 719.3m / Total Current Liabilities 24.1m)
Debt / Equity = 0.02 (Debt 17.4m / totalStockholderEquity, last quarter 703.6m)
Debt / EBITDA = -8.21 (Net Debt -676.0m / EBITDA 82.4m)
Debt / FCF = -7.76 (Net Debt -676.0m / FCF TTM 87.1m)
Total Stockholder Equity = 677.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.75% (Net Income 64.4m / Total Assets 742.8m)
RoE = 9.51% (Net Income TTM 64.4m / Total Stockholder Equity 677.7m)
RoCE = 11.64% (EBIT 80.9m / Capital Employed (Equity 677.7m + L.T.Debt 17.4m))
RoIC = 9.44% (NOPAT 63.9m / Invested Capital 677.7m)
WACC = 8.43% (E(432.3m)/V(449.7m) * Re(8.77%) + (debt cost/tax rate unavailable))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.12%
[DCF] Terminal Value 79.87% ; FCFF base≈87.1m ; Y1≈107.4m ; Y5≈182.9m
[DCF] Fair Price = 115.5 (EV 2.84b - Net Debt -676.0m = Equity 3.52b / Shares 30.5m; r=8.43% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 46.06 | EPS CAGR: 33.46% | SUE: 0.52 | # QB: 0
Revenue Correlation: 46.49 | Revenue CAGR: -8.62% | SUE: 0.17 | # QB: 0
EPS next Year (2026-12-31): EPS=-3.89 | Chg7d=-0.450 | Chg30d=-0.947 | Revisions Net=+6 | Growth EPS=-265.8% | Growth Revenue=-96.4%